Ligand Pharmaceuticals Incorporated (LGND)

From the record

Ligand Pharmaceuticals Incorporated's filings since 2017 show 1 warning event: a debt default or acceleration notice (8-K item 2.04, the latest 2018-04-13) (its current reports).

From the record

Ligand Pharmaceuticals Incorporated's 10 filed years say what it did: revenue went from $109 million in fiscal 2016 to $268 million in fiscal 2025, up 10.5% a year; it rose in 6 of 9 years; the deepest fall was 52% from fiscal 2018 to fiscal 2019; net income was positive in 6 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Ligand Pharmaceuticals Incorporated's diluted share count grew about 6.4% a year, and dividends and buybacks returned about 8% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 149 sales (121 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ligand Pharmaceuticals Incorporated earned about 12 cents of profit for every dollar of shareholders' money. Leverage: it owed about 35 cents per dollar of assets, and net share issuance: its share count grew 11.0% over the year (the filed statements).

From the record

Ligand Pharmaceuticals Incorporated's standing among 315 graded names in its industry family: revenue of $268 million in fiscal 2025 ranks in the top 25% by size; a net margin of 46.4% ranks in the top 5%; revenue growth of 11% a year over the last 3 filed years ranks in the top 47% (its annual reports).

From the record

Ligand Pharmaceuticals Incorporated's leadership, from its insiders' filings and its current reports: the chief executive on the record is Davis, Todd C (Chief Executive Officer, as filed), filing under that title since 2022-12-06, 3.9 years (bottom 41% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 12.5 years (top 4%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Ligand Pharmaceuticals Incorporated's room to grow, from the newest filed statements (fiscal 2025): cash of $175 million against no long-term debt tagged leaves 11.2% of its assets as net cash, bottom 28% of its family; cash from operations less capital spending is 18.2% of revenue (top 16%); research spending of 30.3% of revenue (bottom 34%) (its annual report).

From the record

Ligand Pharmaceuticals Incorporated's growth drivers, from the filed years to fiscal 2025: revenue grew 11% a year over the last three filed years against 10.5% over all 10, speeding up (top 29% of its family); the newest year grew 60.5% (top 22%); research spending grew 31% a year (top 14%); capital spending grew -70.7% a year (bottom 5%) (its annual reports). Ligand Pharmaceuticals Incorporated reported 13 product lines in fiscal 2025: Material Sales Captisol at $40 million (15%), Material Sales Captisol Core at $40 million (15%), Royalty Kyprolis at $36 million (13%), and 10 more; 10 of 13 grew against the year before (its annual report).

From the record

Ligand Pharmaceuticals Incorporated's newest year against its own record: revenue of $268 million in fiscal 2025 came in 73.8% above the $154 million its prior three years' pace pointed to (top 18% of its family); net income of $124 million against a prior three-year average of $5 million (top 2%); a net margin of 46.4% against 6.8% before (top 39%) (its annual reports).